Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variation in the HR region of the env gene of HIV: A perspective for resistance to HIV fusion inhibitors.

AIDS research and human retroviruses - 1 Jan 2011

Qadir M I, Malik S A

Abstract excerpt

HIV fusion inhibitors may be classified into three groups. Peptides binding to HR1 include T1249, C30, and T20 (enfuvirtide). Peptides binding to HR2 include 5-helix. XTT formazan, NB-2, and NB-64 are nonpeptide fusion inhibitors. Genotypic testing for drug resistance is used more commonly than phenotypic testing because of its lower cost, wider availability, and shorter turnaround time. The aim of the study was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Products, env
Share to HIV
Share to HIV Fusion Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to Microbial Sensitivity Tests

Share to Molecular Sequence Data

Share to RNA, Viral

Share to Sequence Analysis, DNA

Source

Identifiers

PMID: 20874419
DOI: 10.1089/aid.2010.0098

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variation in the HR region of the env gene of HIV: A perspective for resistance to HIV fusion inhibitors.PMID 20874419Read ↗

Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates.Semantic proximity Read ↗

HIV fusion and its inhibition in antiretroviral therapySemantic proximity Read ↗

Are fusion inhibitors active against all HIV variants?Semantic proximity Read ↗

Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.Semantic proximity Read ↗

Enfuvirtide (T-20) resistance-related mutations in HIV type 1 subtypes B, C, and F isolates from Brazilian patients failing HAART.Semantic proximity Read ↗

Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.Semantic proximity Read ↗

HIV entry inhibitors: mechanisms of action and resistance pathwaysSemantic proximity Read ↗

Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.Semantic proximity Read ↗

Genotypic analysis of the gp41 HR1 region from HIV-1 isolates from enfuvirtide-treated and untreated patients.Semantic proximity Read ↗

[Analysis of the polymorphism of the genome region of HIV-1 encoding the fusion protein].Semantic proximity Read ↗

Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors.Semantic proximity Read ↗

gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.